S&P 500   4,284.78 (+1.51%)
DOW   33,741.04 (+2.06%)
QQQ   354.91 (+0.82%)
AAPL   180.83 (+0.41%)
MSFT   334.44 (+0.56%)
META   274.39 (+0.65%)
GOOGL   125.33 (+1.30%)
AMZN   125.04 (+1.85%)
TSLA   216.62 (+4.39%)
NVDA   394.61 (-0.78%)
NIO   7.70 (+2.12%)
BABA   85.28 (+2.75%)
AMD   119.25 (-0.18%)
T   15.13 (-4.30%)
F   12.46 (+2.89%)
MU   68.97 (-0.17%)
CGC   0.84 (+0.86%)
GE   106.46 (+1.71%)
DIS   91.12 (+2.86%)
AMC   4.55 (+0.00%)
PFE   38.43 (+1.08%)
PYPL   64.31 (+2.00%)
NFLX   403.89 (+0.19%)
S&P 500   4,284.78 (+1.51%)
DOW   33,741.04 (+2.06%)
QQQ   354.91 (+0.82%)
AAPL   180.83 (+0.41%)
MSFT   334.44 (+0.56%)
META   274.39 (+0.65%)
GOOGL   125.33 (+1.30%)
AMZN   125.04 (+1.85%)
TSLA   216.62 (+4.39%)
NVDA   394.61 (-0.78%)
NIO   7.70 (+2.12%)
BABA   85.28 (+2.75%)
AMD   119.25 (-0.18%)
T   15.13 (-4.30%)
F   12.46 (+2.89%)
MU   68.97 (-0.17%)
CGC   0.84 (+0.86%)
GE   106.46 (+1.71%)
DIS   91.12 (+2.86%)
AMC   4.55 (+0.00%)
PFE   38.43 (+1.08%)
PYPL   64.31 (+2.00%)
NFLX   403.89 (+0.19%)
S&P 500   4,284.78 (+1.51%)
DOW   33,741.04 (+2.06%)
QQQ   354.91 (+0.82%)
AAPL   180.83 (+0.41%)
MSFT   334.44 (+0.56%)
META   274.39 (+0.65%)
GOOGL   125.33 (+1.30%)
AMZN   125.04 (+1.85%)
TSLA   216.62 (+4.39%)
NVDA   394.61 (-0.78%)
NIO   7.70 (+2.12%)
BABA   85.28 (+2.75%)
AMD   119.25 (-0.18%)
T   15.13 (-4.30%)
F   12.46 (+2.89%)
MU   68.97 (-0.17%)
CGC   0.84 (+0.86%)
GE   106.46 (+1.71%)
DIS   91.12 (+2.86%)
AMC   4.55 (+0.00%)
PFE   38.43 (+1.08%)
PYPL   64.31 (+2.00%)
NFLX   403.89 (+0.19%)
S&P 500   4,284.78 (+1.51%)
DOW   33,741.04 (+2.06%)
QQQ   354.91 (+0.82%)
AAPL   180.83 (+0.41%)
MSFT   334.44 (+0.56%)
META   274.39 (+0.65%)
GOOGL   125.33 (+1.30%)
AMZN   125.04 (+1.85%)
TSLA   216.62 (+4.39%)
NVDA   394.61 (-0.78%)
NIO   7.70 (+2.12%)
BABA   85.28 (+2.75%)
AMD   119.25 (-0.18%)
T   15.13 (-4.30%)
F   12.46 (+2.89%)
MU   68.97 (-0.17%)
CGC   0.84 (+0.86%)
GE   106.46 (+1.71%)
DIS   91.12 (+2.86%)
AMC   4.55 (+0.00%)
PFE   38.43 (+1.08%)
PYPL   64.31 (+2.00%)
NFLX   403.89 (+0.19%)
NASDAQ:ORGO

Organogenesis (ORGO) Price Target & Analyst Ratings

$3.88
+0.20 (+5.43%)
(As of 01:15 PM ET)
Compare
Today's Range
$3.68
▼
$3.99
50-Day Range
$1.89
▼
$3.99
52-Week Range
$1.79
▼
$6.52
Volume
524,462 shs
Average Volume
1.21 million shs
Market Capitalization
$509.29 million
P/E Ratio
35.28
Dividend Yield
N/A
Price Target
$10.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

Organogenesis Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 2 Analyst Ratings

Consensus Analyst Price Target

$10.00
157.73% Upside
High Prediction$10.00
Average Prediction$10.00
Low Prediction$10.00
TypeCurrent
6/2/22 to 6/2/23		1 Month Ago
5/3/22 to 5/3/23		3 Months Ago
3/4/22 to 3/4/23		1 Year Ago
6/2/21 to 6/2/22
Consensus Rating
Moderate Buy
Hold
Hold
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$10.00$11.00$11.00$23.00
Predicted Upside157.73% Upside252.56% Upside252.56% Upside92.31% Upside
Get Organogenesis Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.


ORGO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ORGO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Organogenesis Stock vs. The Competition

TypeOrganogenesisMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside171.74% Upside1,273.91% Upside203.34% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/23/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Buy$10.00+190.70%
8/10/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform
(Data available from 6/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ORGO Price Target - Frequently Asked Questions

What is Organogenesis's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Organogenesis stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for ORGO. The average twelve-month price prediction for Organogenesis is $10.00 with a high price target of $10.00 and a low price target of $10.00. Learn more on ORGO's analyst rating history.

Do Wall Street analysts like Organogenesis more than its competitors?

Analysts like Organogenesis less than other Medical companies. The consensus rating for Organogenesis is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how ORGO compares to other companies.

Is Organogenesis being upgraded by Wall Street analysts?

Over the previous 90 days, Organogenesis's stock had 1 upgrade by analysts.

Does Organogenesis's stock price have much upside?

According to analysts, Organogenesis's stock has a predicted upside of 190.70% based on their 12-month price targets.

What analysts cover Organogenesis?

Organogenesis has been rated by BTIG Research in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:ORGO) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -